Arcellx Inc (ACLX) Stock Forecast & Price Target

Compare

302 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACLX Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Arcellx

Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACLX Stock 12 Month Forecast

Average Price Target

$113.33

▲(63.14% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Arcellx Inc in the last 3 months. The average price target is $113.33 with a high forecast of $130.00 and a low forecast of $100.00. The average price target represents a 63.14% change from the last price of $69.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","77":"$77","95":"$95","113":"$113","131":"$131"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$113.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,77,95,113,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.47,74.12615384615384,78.7823076923077,83.43846153846154,88.09461538461538,92.75076923076924,97.40692307692308,102.06307692307692,106.71923076923076,111.37538461538462,116.03153846153846,120.68769230769232,125.34384615384616,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.47,72.84384615384616,76.2176923076923,79.59153846153846,82.96538461538461,86.33923076923077,89.71307692307693,93.08692307692309,96.46076923076923,99.83461538461538,103.20846153846153,106.5823076923077,109.95615384615385,{"y":113.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.47,71.81846153846153,74.16692307692307,76.51538461538462,78.86384615384615,81.21230769230769,83.56076923076922,85.90923076923076,88.25769230769231,90.60615384615384,92.95461538461538,95.30307692307693,97.65153846153845,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.28,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.47,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$113.33

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

John Newman

Canaccord Genuity

$130

Buy

87.13%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Wave Life Sciences (NASDAQ: WVE) and Arcellx Inc (NASDAQ: ACLX)

Geoff Meacham

Citi

$110

Buy

58.34%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Steris (NYSE: STE), Arcellx Inc (NASDAQ: ACLX) and BioCryst (NASDAQ: BCRX)

Michael Schmidt

Guggenheim

$120

Buy

72.74%

Upside

Reiterated

01/21/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Glaukos (GKOS)

Emily Bodnar

H.C. Wainwright

$115

Buy

65.54%

Upside

Reiterated

01/21/26

Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX)

Michael Yee

UBS

$100

Buy

43.95%

Upside

Initiated

01/07/26

Arcellx assumed with a Buy at UBSArcellx assumed with a Buy at UBS

Yanan Zhu

Wells Fargo

$120→$100

Buy

43.95%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Arcellx Inc (NASDAQ: ACLX)

Biren Amin

Piper Sandler

$115

Buy

65.54%

Upside

Reiterated

12/16/25

Arcellx Inc (ACLX) Gets a Buy from Piper Sandler

Cory Kasimov

Evercore ISI

$115

Buy

65.54%

Upside

Reiterated

12/08/25

Evercore ISI Keeps Their Buy Rating on Arcellx Inc (ACLX)

Sami Corwin

William Blair

Buy

―

Reiterated

12/08/25

Arcellx Inc's Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships

Gil Blum

Needham

$105

Buy

51.14%

Upside

Reiterated

12/08/25

Arcellx Inc's Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

12/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Fulcrum Therapeutics (NASDAQ: FULC) and Arcellx Inc (NASDAQ: ACLX)

Jason Gerberry

Bank of America Securities

$112

Buy

61.22%

Upside

Reiterated

12/07/25

Arcellx Inc's Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target

Tyler Van Buren

TD Cowen

Buy

―

Initiated

12/07/25

Judah Frommer

Morgan Stanley

$111

Buy

59.78%

Upside

Reiterated

12/07/25

Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements

Stephen Willey

Stifel Nicolaus

$129→$127

Buy

82.81%

Upside

Reiterated

11/25/25

Stifel Nicolaus Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

John Newman

Canaccord Genuity

$130

Buy

87.13%

Upside

Reiterated

02/02/26

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Wave Life Sciences (NASDAQ: WVE) and Arcellx Inc (NASDAQ: ACLX)

Geoff Meacham

Citi

$110

Buy

58.34%

Upside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Steris (NYSE: STE), Arcellx Inc (NASDAQ: ACLX) and BioCryst (NASDAQ: BCRX)

Michael Schmidt

Guggenheim

$120

Buy

72.74%

Upside

Reiterated

01/21/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Glaukos (GKOS)

Emily Bodnar

H.C. Wainwright

$115

Buy

65.54%

Upside

Reiterated

01/21/26

Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX)

Michael Yee

UBS

$100

Buy

43.95%

Upside

Initiated

01/07/26

Arcellx assumed with a Buy at UBSArcellx assumed with a Buy at UBS

Yanan Zhu

Wells Fargo

$120→$100

Buy

43.95%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Arcellx Inc (NASDAQ: ACLX)

Biren Amin

Piper Sandler

$115

Buy

65.54%

Upside

Reiterated

12/16/25

Arcellx Inc (ACLX) Gets a Buy from Piper Sandler

Cory Kasimov

Evercore ISI

$115

Buy

65.54%

Upside

Reiterated

12/08/25

Evercore ISI Keeps Their Buy Rating on Arcellx Inc (ACLX)

Sami Corwin

William Blair

Buy

―

Reiterated

12/08/25

Arcellx Inc's Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships

Gil Blum

Needham

$105

Buy

51.14%

Upside

Reiterated

12/08/25

Arcellx Inc's Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

12/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Fulcrum Therapeutics (NASDAQ: FULC) and Arcellx Inc (NASDAQ: ACLX)

Jason Gerberry

Bank of America Securities

$112

Buy

61.22%

Upside

Reiterated

12/07/25

Arcellx Inc's Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target

Tyler Van Buren

TD Cowen

Buy

―

Initiated

12/07/25

Judah Frommer

Morgan Stanley

$111

Buy

59.78%

Upside

Reiterated

12/07/25

Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements

Stephen Willey

Stifel Nicolaus

$129→$127

Buy

82.81%

Upside

Reiterated

11/25/25

Stifel Nicolaus Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ACLX Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACLX has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACLX average Analyst price target in the past 3 months is 113.33.

Each month's total comprises the sum of three months' worth of ratings.

ACLX Financial Forecast

ACLX Earnings Forecast

Next quarter’s earnings estimate for ACLX is -$1.04 with a range of -$1.22 to -$0.69. The previous quarter’s EPS was -$0.99. ACLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ACLX has Performed in-line its overall industry.

ACLX Sales Forecast

Next quarter’s sales forecast for ACLX is $12.08M with a range of $0.00 to $58.00M. The previous quarter’s sales results were $4.95M. ACLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ACLX has Performed in-line its overall industry.

ACLX Stock Forecast FAQ

What is ACLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcellx Inc’s 12-month average price target is 113.33.

What is ACLX’s upside potential, based on the analysts’ average price target?

Arcellx Inc has 63.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACLX a Buy, Sell or Hold?

Arcellx Inc has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Arcellx Inc’s price target?

The average price target for Arcellx Inc is 113.33. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $100.00. The average price target represents 63.14% Increase from the current price of $69.47.

What do analysts say about Arcellx Inc?

Arcellx Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of ACLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arcellx Inc (ACLX) Stock Forecast & Price Target

ACLX Analyst Ratings

ACLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

ACLX Analyst Recommendation Trends

ACLX Financial Forecast

ACLX Earnings Forecast

ACLX Sales Forecast

ACLX Stock Forecast FAQ

Detailed List of Analyst Forecasts